Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

NCT04091126 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Belantamab mafodotin
DRUG: Bortezomib
DRUG: Lenalidomide
DRUG: Dexamethasone

Sponsor

GlaxoSmithKline